- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
NanoViricides, Inc. (the "Company"), announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).
This was a joint meeting, co-sponsored by the Office of AIDS Research, National Institutes of Health (NIH), the Division of AIDS, National Institute of Allergy and Infectious Diseases of the NIH, and ASNM. The conference was held at the Bolger Center, Washington, DC, October 14-16, 2010. Anil R Diwan, PhD, President of the Company, spoke in the panel on "Policy, Patents, and Commercialization". The panel covered the business challenges that nanomedicine companies face in bringing leading edge medical products into commercialization.
"Nanomedicines represent the next therapeutic plateau in the treatment of many diseases," said Dr. Diwan, adding, "The level of effectiveness achieved with these novel, targeted, specific, therapies is far greater than what has been attained thus far."
Dr. Diwan reviewed the accomplishments of NanoViricides, Inc. He discussed the platform technology upon which the nanoviricides(R) drug candidates are based. Nanoviricides are designed to complete the job of rendering the virus particle non-infectious without assistance from the immune system, he said. A nanoviricide accomplishes this by mimicking the features of the cell surface to which a virus binds. He presented the very promising results obtained by the Company in testing its nanoviricides drug candidates against a number of diseases including Influenza, viral diseases of the Eye, Herpes Simplex Virus (HSV), Dengue Virus, and HIV. He then went on to discuss the challenges faced by nanomedicine companies in commercializing novel, cutting edge therapies. The presentation was attended by leading scientists in the field of nanomedicine as well as scientists from the sponsoring NIH agencies. The presentation was well received.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
About the American Society for NanoMedicine (ASNM)
The American Society for NanoMedicine (ASNM) is a professional, academic and medical society dedicated to advancing research in nanomedicine. It comprises of members drawn from throughout the fields of nanotechnology, engineering, and the biomedical sciences with the common goal of advancing nanomedicine research for the realization of the potential it has to benefit the global community. ASNM is an open, democratic, and professional nonprofit organization.
For more information, please click here
Amanda Schuon, 310-550-7200
Copyright © NanoViricidesIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
FEI Launches Apreo – Industry-Leading Versatile, High-Performance SEM: The Apreo SEM provides high-resolution surface information with excellent contrast, and the flexibility to accommodate a large range of samples, applications and conditions May 4th, 2016
Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016
Introducing the RE標ORK Bio-inspired Robotics Summit in Berlin April 27th, 2016